ALC

Business Context and Reporting Period

Company: Alcon, Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: Alcon is a global medical specialty company focused on eye care, developing, manufacturing, and marketing pharmaceuticals, surgical equipment/devices, and contact lens care products. The company operates in over 180 countries through two segments: Alcon United States and Alcon International. In March 2002, Alcon completed its Initial Public Offering (IPO), transitioning from a wholly-owned subsidiary of Nestlé S.A. to a publicly traded entity, though Nestlé retained approximately 74.5% ownership.

Key Financial Metrics (Year Ended Dec 31, 2002)

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 9.5% (10.0% in constant currency) driven primarily by the pharmaceutical segment, which grew 17.4%. Key growth drivers included the launch of TRAVATAN® (glaucoma) and Patanol® (allergy).
• Profitability: Net earnings surged 47.9% to $466.9 million. This increase was significantly aided by the adoption of FASB Statement No. 142, which eliminated goodwill amortization, providing a favorable impact of approximately $42.5 million to operating income.
• Debt Structure: Long-term debt decreased significantly from $697.4 million to $80.8 million, while short-term borrowings increased to $1,772.8 million. This shift reflects the use of IPO proceeds to redeem preferred shares and repay long-term obligations, alongside increased reliance on a $2.0 billion commercial paper facility.
• Product Recall: The company incurred $25.9 million in costs related to the voluntary recall and termination of the SKBM® microkeratome product line in Q4 2002.
• Segment Performance: Alcon United States operating income grew 24.0%, while Alcon International grew 5.5%, impacted by currency fluctuations and economic conditions in Latin America and Japan.

Guidance, Outlook, and Risks

• Dividend Policy: Management expects to declare a dividend from 2002 operations of CHF 0.45 per share (approx. $0.33), payable in June 2003, subject to shareholder approval.
• Outlook: The company anticipates continued growth in pharmaceuticals and cataract surgery. However, sales of laser refractive surgical products remain sensitive to economic conditions and consumer confidence.
• Key Risks:
  • Patent Expirations: Patents covering approximately 6.3% of 2002 sales are set to expire within three years, potentially inviting generic competition.
  • Regulatory & Reimbursement: Pressure from third-party payors and government price controls (particularly in Japan and the EU) may reduce profitability. FDA approval timelines for new products remain uncertain.
  • Currency Fluctuations: As a global company with significant exposure to the Euro and Japanese Yen, exchange rate volatility impacts reported results.
  • Supply Chain: Reliance on single-source suppliers for active ingredients and single-source manufacturing facilities creates operational risks.

Investor Verification Checklist

• Pro Forma Adjustments: Verify the impact of the FASB 142 accounting change on reported earnings versus pro forma earnings to understand organic growth.
• SKBM® Recall Costs: Confirm the total one-time charges ($25.9 million) and assess if any residual liabilities remain regarding the microkeratome recall.
• Debt Maturity Profile: Review the maturity schedule of the $1.77 billion in short-term borrowings and the reliance on the Nestlé-guaranteed commercial paper facility.
• Patent Cliff: Identify specific products facing patent expiration in the next 36 months and the status of replacement product pipelines.
• Dividend Approval: Monitor the outcome of the May 20, 2003, shareholder meeting regarding the proposed dividend declaration.